Machine Learning

One CEO's shift from overworked operator to visionary leader sparked a 40% revenue surge. The secret? A structured system rooted in performance science.

The AI leasing platform's SOC 2 Type II compliance removes a critical barrier, building the trust needed for widespread adoption in the multifamily sector.

A new partnership combines clinical care with logistical support, aiming to solve the caregiving puzzle for employers and their increasingly stressed employees.

A new bispecific antibody aims to treat the 50% of AxSpA patients who find no relief, as Fortitude Biomedicines enters a competitive autoimmune market.

A US-Uruguay collaboration is using novel REJOIN-seq tech to find hidden RNA triggers of lupus, paving the way for safer, non-immunosuppressive drugs.

A new partnership brings a groundbreaking protocol for corneal blindness to Chicago, expanding a national network dedicated to restoring vision for thousands.

A new joint venture aims to power LA's AI boom by injecting 32MW of critical data center capacity into one of the nation's most constrained markets.

The wealth tech leader unveils its InsightX platform and AI Innovation Lab, designed to make advanced analytics accessible to all financial professionals.

As AI rewires public thought, a new platform launches a training system to build cognitive independence and help users think clearly in a manipulative world.

With new funding led by Telegraph Hill Partners, Kytopen is scaling its Flowfect® tech to make advanced cell therapies faster, cheaper, and more accessible.

Language services leader GLOBO hires a new CTO with deep AI expertise, signaling a major push to revolutionize communication for underserved populations.

As AI struggles to separate medical fact from fiction, a new .med domain offers a structural signal of trust, aiming to protect patients and verify sources.

A new partnership aims to tame AI for FinTech with a code-first approach, promising greater governance, agility, and cost savings over rigid SaaS platforms.

AIRNA has dosed the first patient with AIR-001, an RNA-editing drug that could treat both the lung and liver damage of a devastating genetic disease.

A new Montreal-based collaboration aims to use advanced AI and a unique dataset to make drug development faster, smarter, and safer for patients.

The firm adds veteran TD Cowen analyst Boris Peaker to deepen its research in oncology and genetic medicines, signaling a major bet on specialized insight.

Avaí Bio and Austrianova are set to present new findings on a novel cell-based therapy designed to produce the 'longevity protein' Klotho.

In a major strategic move, Premier Research appoints Paul Spreen as CCO, signaling a bold push to capture the rebounding biotech market.

With new clinical trial data showing its AI is superior for complex AFib, Volta Medical heads to a major conference to change the standard of care.

The new algorithm aims to systematically filter out harmful interactions and reduce hidden trading costs in the complex world of off-exchange trading.